Aytu biopharma reports second quarter of fiscal year 2023

Second consecutive quarter of positive adjusted ebitda quarterly net revenue of $26.3 million driven by 23% growth in rx segment company to host conference call today at 5:00pm et englewood, co / accesswire / february 21, 2023 / aytu biopharma, inc. (the company or "aytu") (nasdaq:aytu), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced financial and operational results for the quarter ended december 31, 2022. q2 2023 commercial highlights (3 months ending december 31, 2022) total net revenue was $26.3 million, an increase of 14% over the $23.1 million in net revenue in the year ago quarter.
AYTU Ratings Summary
AYTU Quant Ranking